Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373055 | 0.84 | CFTR (0.55) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14861898 | 0.84 | CFTR (0.55) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16389665 | 0.82 | AGBL2 (0.54) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29699314 | 0.82 | CFTR (0.56) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2373041 | 0.82 | CFTR (0.56) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30134211 | 0.81 | MAPT (0.47) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9928605 | 0.81 | MAPT (0.47) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14783550 | 0.80 | CFTR (0.65) | CFTRKDM4ESMN1; SMN2ALDH1A1AGBL2 | |
| SCHEMBL1865699 | 0.80 | SMN1; SMN2 (0.53) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL707954 | 0.79 | MAPT (0.46) | CFTRKDM4EMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-9248122-B2 | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-2925759-A1 | HETEROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014082738-A1 | HETEROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148478-A1 | HETEROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148478-A1 | HETEROQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | CFTR 318/4885KDM4E 908/4885MAPT 3408/4885 |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CFTR 382/4885KDM4E 1198/4885MAPT 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.